Examples: alirocumab, evolocumab

Effect: LDL-C lowering 50-70%

Conditions:

• Dyslipidemia (2ed/3rd line treatment)
  • Risk factor for CAD

MOA: mab against PCSK9 (break down LDLR) ****→ increase LDL uptake from blood

• (’-cumab’) = humanized mab

Admin: SC

Pro: No CI

Con: Expensive

Side effects: hypersensitivity (A>E)

CI: N/A